All In Biotech

Drug Trial Radar · NCT03881488

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

100

Actual

Start

May 17, 2019

Primary completion

May 21, 2025

Study completion May 21, 2025

Sponsor

Lead sponsor
Compass TherapeuticsIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd; Merck, Sharp & Dohme, LLC, Rahway, NJ USA
First posted
Mar 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In each arm (monotherapy and combination therapy), data from Part 1 (dose escalation) and Part 2 (dose expansion) were combined by dose level for reporting.

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Cancer
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Mesothelioma
  • Melanoma
  • Head and Neck Cancer

Interventions

  • CTX-471Drug

    IV infusion every 2 weeks

  • Pembrolizumab (KEYTRUDA®)Drug

    IV infusion every 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), and/or Changes in Clinical Laboratory AbnormalitiesTime frame: From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Ocala Oncology Center

    Ocala, Florida

  • Hematology Oncology Associates Of The Treasure Coast

    Port Saint Lucie, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine, Siteman Cancer Center

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mt Sinai

    New York, New York

  • Duke University School of Medicine

    Durham, North Carolina

  • Institute for Translational Oncology Research (ITOR)

    Greenville, South Carolina

  • Mary Crowley Cancer Research

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.